Studies assess linagliptin treatment in adults with type 2 diabetes (T2D), as well as add-on to basal insulin therapy

RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 2, 2012 /PRNewswire/ — Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announce data from three pooled analyses for linagliptin …